Zacks Research Forecasts Sanofi's Q1 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY - Free Report) - Stock analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of Sanofi in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now expects that the company will earn $0.85 per share for the quarter, up from their prior forecast of $0.84. The consensus estimate for Sanofi's current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi's Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th.

Sanofi Price Performance

Shares of NASDAQ SNY traded up $0.86 during trading hours on Monday, reaching $53.34. 3,039,218 shares of the stock traded hands, compared to its average volume of 2,545,458. The company's 50-day simple moving average is $48.70 and its two-hundred day simple moving average is $52.20. The company has a market capitalization of $135.37 billion, a P/E ratio of 27.21, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter last year, the business posted $2.55 earnings per share. The company's revenue for the quarter was up 12.3% on a year-over-year basis.

Institutional Investors Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of SNY. Jennison Associates LLC lifted its position in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock valued at $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock valued at $82,366,000 after buying an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC boosted its position in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after buying an additional 664,455 shares during the period. JPMorgan Chase & Co. grew its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.